glutathione inhibitor cancer responsive nanomedicine leverages tumor redox imbalance for targeted theranostics | Discover Oncology Glutathione-mediated nanomedicines for cancer diagnosis
Description
doi: 10.1038/s41571-021-00585-y
In: Albert DM, Miller JW, Azar DT, Young LH, editors
PMID: 19908318
In the day 430 post-injury study (iii), BPC 157 rats rapidly presented tail function recovery, and no demyelination process (Luxol fast blue staining)
Cells were imaged with microscope
This is generally due to the fact that although all possible genetic manipulation procedures and metabolic engineering strategies are used in natural strains, sometimes the production titer of the required metabolites is still very low or does not meet the requirements
